Definitive Healthcare Corp. (NASDAQ:DH) Short Interest Update

Definitive Healthcare Corp. (NASDAQ:DH) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,770,000 shares, a growth of 30.0% from the February 13th total of 2,130,000 shares. Based on an average trading volume of 823,600 shares, the days-to-cover ratio is presently 3.4 days. Currently, 6.8% of the shares of the company are sold short.

Institutional Trading of Definitive Healthcare

Several institutional investors and hedge funds have recently modified their holdings of DH. Western Wealth Management LLC purchased a new position in shares of Definitive Healthcare during the 4th quarter valued at about $90,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Definitive Healthcare by 6.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company’s stock valued at $334,000 after buying an additional 4,748 shares in the last quarter. Sone Capital Management LLC purchased a new position in shares of Definitive Healthcare during the 4th quarter valued at about $953,000. Two Sigma Advisers LP raised its holdings in shares of Definitive Healthcare by 1,301.5% during the 4th quarter. Two Sigma Advisers LP now owns 189,200 shares of the company’s stock valued at $778,000 after buying an additional 175,700 shares in the last quarter. Finally, Two Sigma Investments LP raised its holdings in shares of Definitive Healthcare by 2,383.1% during the 4th quarter. Two Sigma Investments LP now owns 285,555 shares of the company’s stock valued at $1,174,000 after buying an additional 274,055 shares in the last quarter. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Stock Up 3.7 %

Shares of NASDAQ DH opened at $2.77 on Wednesday. The business has a 50-day simple moving average of $4.28 and a two-hundred day simple moving average of $4.35. Definitive Healthcare has a 52 week low of $2.55 and a 52 week high of $8.35. The company has a market cap of $312.76 million, a P/E ratio of -0.89, a P/E/G ratio of 4.06 and a beta of 1.51. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.33.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.04). Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The business had revenue of $62.29 million during the quarter, compared to analysts’ expectations of $60.60 million. Research analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DH. Barclays cut their price target on Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research note on Monday, March 3rd. The Goldman Sachs Group cut their price target on Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC reiterated a “hold” rating on shares of Definitive Healthcare in a research note on Thursday, January 16th. Finally, Stephens initiated coverage on Definitive Healthcare in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.35.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.